Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Overview and classification of scleroderma disorders

Christopher P Denton, MD
Section Editor
John S Axford, DSc, MD, FRCP, FRCPCH
Deputy Editor
Monica Ramirez Curtis, MD, MPH


The scleroderma disorders comprise a heterogeneous group of conditions linked by the presence of thickened, sclerotic skin lesions [1]. However, the other manifestations of these conditions are quite diverse. These differences have required the development of a classification system that takes into account the different potential complications, prognoses, and management strategies for patients with these disorders.

The simplest division of the scleroderma-related disorders is into localized and systemic forms of the disease (table 1 and table 2). The term systemic sclerosis (SSc) is more appropriate for the latter forms; it emphasizes that frequent involvement of internal organs is generally the most important manifestation of these conditions.

Disorders other than SSc can cause skin thickening. As examples, scleroderma-like skin changes can occur in some endocrine disorders (eg, diabetes mellitus and hypothyroidism), in end-stage renal disease (nephrogenic systemic fibrosis), and in conjunction with inflammatory (eg, eosinophilic fasciitis) and infiltrative (eg, amyloid) disorders. Sclerodermatous skin changes may occur as a result of exposure to certain drugs, toxins, and environmental exposures. These and other causes of sclerodermatous skin changes or non-sclerodermatous skin thickening are discussed separately. (See "Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Differential diagnosis'.)

This topic will provide an overview of the classification schema of scleroderma. Classification systems that have been developed for diagnostic and research purposes are also discussed.


Localized scleroderma can be divided into linear scleroderma (en coup de sabre) and localized and generalized morpheae (table 1). (See "Localized scleroderma in childhood".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2017. | This topic last updated: Nov 03, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Black CM. Scleroderma--clinical aspects. J Intern Med 1993; 234:115.
  2. Falanga V, Medsger TA Jr, Reichlin M, Rodnan GP. Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med 1986; 104:849.
  3. Black CM. Scleroderma and fasciitis in children. Curr Opin Rheumatol 1995; 7:442.
  4. Falanga V. Localized scleroderma. Med Clin North Am 1989; 73:1143.
  5. Rencic A, Goyal S, Mofid M, et al. Bullous lesions in scleroderma. Int J Dermatol 2002; 41:335.
  6. Hayakawa I, Hasegawa M, Takehara K, Sato S. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma. Arthritis Rheum 2004; 50:227.
  7. Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol 2006; 18:606.
  8. Black CM. Measurement of skin involvement in scleroderma. J Rheumatol 1995; 22:1217.
  9. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202.
  10. Lonzetti LS, Joyal F, Raynauld JP, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum 2001; 44:735.
  11. Silman AJ. Scleroderma. Baillieres Clin Rheumatol 1995; 9:471.
  12. Molina JF, Anaya JM, Cabrera GE, et al. Systemic sclerosis sine scleroderma: an unusual presentation in scleroderma renal crisis. J Rheumatol 1995; 22:557.
  13. Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000; 43:444.
  14. Itoh M, Yanaba K, Kobayashi T, Nakagawa H. Taxane-induced scleroderma. Br J Dermatol 2007; 156:363.
  15. Kallenberg CG, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988; 47:634.
  16. Gendi NS, Welsh KI, Van Venrooij WJ, et al. HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic followup of 46 patients. Arthritis Rheum 1995; 38:259.
  17. Mondini M, Vidali M, De Andrea M, et al. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16. Arthritis Rheum 2006; 54:3939.